These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29304282)

  • 1. Dual Allosteric Inhibition of SHP2 Phosphatase.
    Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
    ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
    Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
    J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
    Jin WY; Ma Y; Li WY; Li HL; Wang RL
    Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
    LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC
    Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
    Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
    J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.
    Pádua RAP; Sun Y; Marko I; Pitsawong W; Stiller JB; Otten R; Kern D
    Nat Commun; 2018 Oct; 9(1):4507. PubMed ID: 30375376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of leukemia-associated SHP2
    Sun X; Ren Y; Gunawan S; Teng P; Chen Z; Lawrence HR; Cai J; Lawrence NJ; Wu J
    Leukemia; 2018 May; 32(5):1246-1249. PubMed ID: 29568093
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
    Chio CM; Lim CS; Bishop AC
    Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
    Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
    Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
    Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
    Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition.
    Yangchun M; WenYu Y; Liang Z; LiPeng L; JingWei W; WeiYa L; Shan D; Ying M; RunLing W
    Mol Divers; 2022 Jun; 26(3):1567-1580. PubMed ID: 34338914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
    Tang K; Zhao M; Wu YH; Wu Q; Wang S; Dong Y; Yu B; Song Y; Liu HM
    Eur J Med Chem; 2022 Feb; 230():114106. PubMed ID: 35063735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
    Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
    J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel PROTACs for degradation of SHP2 protein.
    Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
    Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.
    Bagdanoff JT; Chen Z; Acker M; Chen YN; Chan H; Dore M; Firestone B; Fodor M; Fortanet J; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu S; Mohseni M; Ntaganda R; Sarver P; Smith T; Sendzik M; Stams T; Spence S; Towler C; Wang H; Wang P; Williams SL; LaMarche MJ
    J Med Chem; 2019 Feb; 62(4):1781-1792. PubMed ID: 30688462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2).
    Day JEH; Berdini V; Castro J; Chessari G; Davies TG; Day PJ; St Denis JD; Fujiwara H; Fukaya S; Hamlett CCF; Hearn K; Hiscock SD; Holvey RS; Ito S; Kandola N; Kodama Y; Liebeschuetz JW; Martins V; Matsuo K; Mortenson PN; Muench S; Nakatsuru Y; Ochiiwa H; Palmer N; Peakman T; Price A; Reader M; Rees DC; Rich SJ; Shah A; Shibata Y; Smyth T; Twigg DG; Wallis NG; Williams G; Wilsher NE; Woodhead A; Shimamura T; Johnson CN
    J Med Chem; 2024 Mar; 67(6):4655-4675. PubMed ID: 38462716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.
    Luo R; Fu W; Shao J; Ma L; Shuai S; Xu Y; Jiang Z; Ye Z; Zheng L; Zheng L; Yu J; Zhang Y; Yin L; Tu L; Lv X; Li J; Liang G; Chen L
    Eur J Med Chem; 2023 May; 253():115305. PubMed ID: 37023678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules.
    Guo Z; Duan Y; Sun K; Zheng T; Liu J; Xu S; Xu J
    Eur J Med Chem; 2024 Sep; 275():116579. PubMed ID: 38889611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
    LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
    J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.